Inclusion Criteria

Inclusion Criteria

Patients must have:

- HIV-positivity.

- Diagnosed KS proven by biopsy.

- NOTE:

- Patients must not opt for immediate topical, systemic or radiation treatment.

- At least 4 cutaneous lesions not treated within the previous 4 weeks.

- Life expectancy > 6 months.

- Signed, informed consent from parent or legal guardian for those patients < 18 years
of age.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions and symptoms are excluded:

- Neoplastic disease (excluding KS) requiring systemic cytotoxic or radiation therapy
or who have had these therapies within 1 month of baseline and have not completely
recovered from the effects of these therapies.

- Unstable or severe intercurrent medical conditions, including but not limited to,
significant symptomatic visceral KS.

- Clinically significant malabsorption syndrome.

- Renal insufficiency.

Patients with any of the following prior conditions are excluded:

Significant Fever (> 101 degrees F (38 degrees C) for >= 7 days) and/or diarrhea (> 6
loose stools/day for >= 7 days) within one month of baseline.

1. Immediate topical or systemic treatment for KS lesions.

- Use of Retinoid class drugs, either topically or systemically, or beta-carotene
compounds or Vitamin A doses of more than 15,000 IU (5,000 mcg) per day concurrently.

Immediate radiation treatment.

1. Treatment of KS lesions with intra-lesional chemotherapy within 4 weeks of entry.

- History of > 2 weeks of prior therapy with Indinavir or Ritonavir.

- Use of Retinoid class drugs, either topically or systemically, or beta-carotene
compounds or Vitamin A doses of more than 15,000 IU (5,000 mcg) per day within 4
weeks of entry.

Treatment of KS lesions with radiation within 4 weeks of entry. Active substance abusers;
urine drug tests may be performed if drug abuse is suspected.